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Abstract 
An increase in the interaction between advanced glycation end-products (AGEs) and their receptor RAGE is believed to con-
tribute to the pathogenesis of chronic complications of Diabetes mellitus, which can include bone alterations such as osteopenia. 
We have recently found that extracellular AGEs can directly regulate the growth and development of rat osteosarcoma UMRl 06 
cells, and of mouse calvaria-derived MC3T3El osteoblasts throughout their successive developmental stages (proliferation, 
differentiation and mineralisation), possibly by the recognition of AGEs moieties by specific osteoblastic receptors which are 
present in both cell lines. In the present study we examined the possible expression of RAGE by UMR106 and MC3T3El 
osteoblastic cells, by immunoblot analysis. We also investigated whether short-, medium- or long-term exposure of osteoblasts 
to extracellular AGEs, could modify their affinity constant and maximal binding for AGEs (by 125I-AGE-BSA binding experi-
ments), their expression of RAGE (by immunoblot analysis) and the activation status of the osteoblastic ERK 1/2 signal trans-
duction mechanism (by immunoblot analysis for ERK and P-ERK). Our results show that both osteoblastic cell lines express 
readily detectable levels of RAGE. Short-term exposure of phenotypically mature osteoblastic UMR106 cells to AGEs de-
crease the cellular density of AGE-binding sites while increasing the affinity of these sites for AGEs. This culture condition 
also dose-dependently increased the expression of RAGE and the activation of ERK. In proliferating MC3T3El pre-osteoblasts, 
24-72 h exposure to AGEs did not modify expression of RAGE, ERK activation or the cellular density of AGE-binding sites. 
However, it did change the affinity of these binding sites for AGEs, with both higher- and lower-affinity sites now being appar-
ent.Medium-term (1 week) incubation of differentiated MC3T3El osteoblasts withAGEs, induced a simultaneous increase in 
RAGE expression and in the relative amount of P-ERK. Mineralising MC3T3El cultures grown for 3 weeks in the presence 
of extracellular AGEs showed a decrease both in RAGE and P-ERK expression. These results indicate that, in phenotypically 
mature osteoblastic cells, changes in ERK activation closely follow the AGEs-induced regulation of RAGE expression. Thus, 
the AGEs-induced biological effects that we have observed previously in osteoblasts, could be mediated by RAGE in the later 
stages of development, and mediated by other AGE receptors in the earlier pre-osteoblastic stage. (Mol Cell Biochem 000: 
000-000,2003) 
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Introduction 
The accumulation of advanced glycation-end-products 
(AGEs) has been postulated to be involved in ageing, Alzhe-
imer's disease and the chronic complications of Diabetes 
mellitus [1, 2]. AGEs, which are formed in part as a conse-
quence of the non-enzymatic glycosylation of proteins, can 
be taken up and removed by specific receptors present in a 
variety of cell types. The occupation of these receptors by 
AGEs may also induce alterations in cell homeostasis by vari-
ous mechanisms, which include regulation of cell surface 
molecules ( tissue factor, V-CAM, I-CAM), of proteases or their 
inhibitors (MMPs, PAI-1 ), of extracellular matrix protein pro-
duction (collagen types I and IV, fibronectin, vitronectin), or 
of cytokine and growth factor secretion (IL-1 and -6, IGF-1, 
PDGF, VEGF, to name a few). Three classes of AGE-receptors 
have been identified·to date: RAGE (receptor for AGEs), a 
45-50 kDa member of'the immunoglobulin superfamily of 
proteins; the AGE-receptor-complex, which consists of oligo-
saccaryl-transferase-48 (OST-48), 80K-H (an 80-87 kDa 
substrate for protein kinase C) and galectin-3 (a 30--35 kDa 
S-lectin); and the class A macrophage scavenger receptor [3-
5]. 
In particular, RAGE-mediated recognition of AGEs has 
been shown to regulate various cellular processes. This path-
way is initiated by AGE-RAGE interaction, and can be fol-
lowed by oxidation of p21 ras through locally produced reactive 
oxygen species (ROS), recruitment of phosphatidyl-inositol-
3' -kinase (PI3K), activation of extracellular signal-regulated 
kinases (ERK), nuclear translocation of the transcription fac-
tor NF-KB, and finally regulation of the expression of tissue-
specific subsets of NF-KB-inducible genes. Interestingly, the 
gene which encodes for RAGE protein possesses cis-acting 
recognition elements for NF-KB in its promoter region. Thus, 
long-term activation of RAGE by its ligands - as could oc-
cur with diabetic AGE-accumulation - has been postulated 
to up-regulate the expression of this receptor, thereby exac-
erbating its cellular effects [3]. 
Our group and other investigators have shown that AGE-
modified proteins can exert direct effects on osteoblast-like 
cells in culture [6-12]. In particular, we have found that solu-
ble AGE-proteins regulate osteoblastic growth in a biphasic 
manner: while initially eliciting an increase in cellular pro-
liferation and differentiation, a relatively long-term incuba-
tion of these cells with AGE-modified proteins induces a 
significant decrease in both parameters of osteoblast devel-
opment [9]. These effects are probably mediated by mem-
brane-associated AGE-specific receptors, which we have 
recently described in osteoblastic cells [13]. The affinity 
constant of these AGE-receptors is differentially regulated 
throughout the successive stages of osteoblastic development 
[13], and this is concordant with the maturation-dependent 
effects induced by AGE on osteoblasts in culture [9, 10, 14]. 
Recently we have also shown that the accumulation of AGE 
on collagen regulates osteoblastic growth, probably through 
the modulation of inducible and endothelial nitric oxide syn-
thase (NOS) expression as well as by intracellular generation 
of reactive oxygen species (ROS) [14]. 
The object of this study was to further investigate the role 
of AGE receptors in the AGE-induced modulation of oste-
oblastic development. To achieve this aim, we initially per-
formedAGE-binding experiments with osteoblasts which had 
been exposed either to control or AGE-modified proteins. 
This allowed us to evaluate possible AGE-induced changes 
both in the maximal binding of AGEs to cells, and in the glo-
bal affinity constant of the osteoblastic AGE receptors/bind-
ing proteins. In other experiments, we assessed the expression 
of RAGE by osteoblast-like cells in culture. We also investi-
gated the regulation of RAGE expression as a consequence 
of short-, medium- or long-term osteoblastic exposure to 
extracellular AGEs, as well as the involvement of ERK acti-
vation as a possible signal transduction pathway for the rec-
ognition of AGEs by receptors such as RAGE. 
Materials and methods 
Materials 
Bovine serum albumin (BSA), ribose, glucose-6-phosphate 
(G6P), Iodo-Gen, Triton X-100, tri-chloro-acetic acid (TCA), 
prestained molecular weight standards, Kodak XAR-5 photo-
graphic film, Sephadex G-25 and G-50 and rat tail acid-
soluble type I collagen were purchased from Sigma (St. 
Louis, MO, USA). Centricon 10 kDa cutoff filter cartridges 
were purchased fromAmicon Inc. (Beverly, MA, USA). Dul-
becco's modified Eagle's medium (DMEM), trypsin-EDTA 
and fetal bovine serum (FBS) were obtained from Gibco (Life 
Technology, Argentina). Tissue culture disposable material 
was from Nunc. Goat polyclonal anti-RAGE and anti-ERKl/ 
2 antibodies, as well as a monoclonal anti-P-ERK antibody, 
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). 125I was from New England Nuclear. All other chemi-
cals and reagents were obtained from commercial sources and 
were of analytical grade. 
Preparation of AGE-modified type I collagen for cell 
matrices and of AGE-modified BSA 
AGE-BSA was prepared as we have previously described [9]. 
Briefly, BSA was incubated for 3-6 weeks in sterile condi-
tions in 150 mM phosphate-buffered-saline (PBS), pH 7.4, 
with 100 mM G6P or ribose at 37°C. G6P or ribose were used 
as glycating sugars instead of glucose, to speed up non-en-
zymatic glycosylation. Control BSA was incubated in the 
same conditions without sugar. At the end of the incubation 
period, BSA and AGE-BSA were separated from non-co-
valently-bound low molecular weight molecules by cen-
trifugation/filtration with Centricon filter cartridges. The 
formation of protein-AGEs was assessed by their character-
istic fluorescence-emission maximum at 420 nm upon exci-
tation at 340 nm [9]. Fluorescence values oftest substances 
were expressed as percentage relative fluorescence. Thus, the 
estimated level of AGE-BSA obtained in this in vitro incu-
bation was 18.5% relative fluorescence intensity/mg protein, 
as opposed to 3.2% for control BSA. 
Type I collagen was solubilized in sterile 0.02 N acetic acid 
(2.5 mg/ml) (pH 3.0), poured into plastic dishes (50 µg/cm2) 
and incubated overnight at 37°C. Collagen formed a thin film 
during incubation [7]. The film was washed with phosphate-
buffered saline (PBS) and further incubated in PBS with or 
without 100 mM ribose at 37°C for 3 weeks in sterile condi-
tions [15]. Finally, the'plates were washed thoroughly with 
DMEM and the cells were plated for different experiments. 
AGE-formation on collagen was monitored by measuring 
AGE-specific fluorescence emission (356 nm excitation 
wavelength and 440 nm emission wavelength), as we have 
previously described [14]. After incubating 3 weeks with 
ribose, collagen contained 4-fold more AGE-associated fluo-
rescence than control collagen incubated with PBS. 
Cell culture 
UMR106 rat osteosarcoma-derived cells were grown in 
75 cm2 plastic flasks at 37°C in a humidified 5% C02 atmos-
phere in DMEM supplemented with 10% FBS, 100 U/mL 
penicillin and 100 mg/L streptomycin. This cell line has been 
shown to conserve certain characteristics of differentiated 
osteoblastic phenotype [160]. After 5-7 days, cells were 
sub-cultured using trypsin/EDTA and replated on plastic, on 
control collagen or on glycated collagen to begin the experi-
ments. MC3T3El non-transformed osteoblastic mouse cal-
varia-derived cells were grown at 37°C in 5% CO!l)MEMI 
10% FBS and antibiotics, and passaged every 4-6 days. Pre-
vious studies have demonstrated that expression of osteob-
lastic markers begins after culturing these cells with medium 
supplemented by J3-glycerol-phosphate and ascorbic acid [17, 
18]. When cells are cultured in these conditions on collagen-
coated plates, ALP begins to be expressed after 5 days. In 
addition, mineralisation is achieved with these cells after 
extending this culture to 20 days. However, the cells only 
undergo active replication during the first 5 days of incuba-
tion. 
To study the effect of AGE-modifies proteins on UMR106 
and MC3T3El osteoblasts, cells were grown under the con-
ditions that we have previously reported [9, 13, 14] for the 
times indicated in each experiment. 
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Radiolabelling of AGE-BSA 
AGE-BSA was iodinated with carrier-free 1251 by the Iodo-
Gen method as we have previously described [13]. Briefly, 
30 µg of AGE-BSA in PBS was incubated with 0.5 mCi car-
rier-free 1251 in an Iodo-Gen-coated vial at room temperature 
for 20 min. To separate free from bound 1251, the sample was 
fractionated by Sephadex G-25 column cromatography, and 
the fraction corresponding to 1251-AGE-BSA was further 
purified by a Sephadex G-50 50 ml column, until > 98% ra-
dioactivity was TCA precipitable. Specific radioactivity of 
labelled 1251-AGE-BSA was between 1.1.104 and 1.8.104 cpm/ 
ng protein. 
125/-AGE-BSA binding studies 
Radioligand binding studies were carried out with UMR106 
and MC3T3El osteoblastic cells, cultured on collagen- or 
AGE-collagen-coated 48-well plates in the conditions de-
scribed in the figures. These displacement studies were per-
formed in 0.25 ml binding medium (RPMI-1640, 25 mM 
Hepes, pH 7.4, 5 g/1 BSA) at 4°C, as previously described 
[13]. Cell monolayers were pre-incubated for 30 min with 
increasing concentrations ofunlabelled AGE-BSA (0-1000 µg 
protein/ml binding medium), following which 106 cpm of 1251-
AGE-BSA was added to each well. After incubating for 2 h 
at 4°C, the supernatant was aspirated and the cell layers were 
washed 3 times each with cold PBS/0.5% BSA, and cold 
PBS alone. Cell monolayers were then solubilized in 0.5 ml 
0.1 % Triton X-100, which was transferred to tubes for count-
ing in a Packard PRIAS gamma counter. Non-specific bind-
ing of 1251-AGE-BSA was determined in parallel incubations 
by adding an excess ofunlabeledAGE-BSA. Specific bind-
ing was defined as the difference between total binding 
(cells incubated with radioligand and a known amount of 
unlabeled AGE-BSA) and non-specific binding (as defined 
above). Specificity of binding for AGE moieties was con-
firmed in certain incubations by adding an excess of con-
trol BSA. 
Western blot analysis of RAGE and P-ERK 
We next evaluated the expression of RAGE by both cell lines, 
the possible effect of an exposure to AGE-modified proteins 
on the expression of this receptor, as well as the activation 
status of the ERK 1/2 transduction pathway. In these experi-
ments, osteoblastic cells growing for different periods of time 
on control or AGE-modified collagen matrices, or growing 
on plastic in serum-free medium with the addition of either 
BSA or AGE-BSA, were lysated in Laemmli's buffer [19] and 
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the protein content was evaluated by the method of Lowry 
[20]. These lysates were heated at 100°C for 3 min and 30 µg 
of protein subjected to 12% SDS-PAGE. The separated pro-
teins were then transferred to nitrocellulose membranes. After 
washing and blocking, the membranes were incubated with 
anti-RAGE polyclonal antibodies, a monoclonal anti-P-ERK 
antibody, or a polyclonal antibody that recognizes both phos-
phorylated and unphosphorylated ERKl/2. Blots were devel-
oped using chemiluminescence reagents. The intensity of the 
specific bands was quantified by densitometry after scanning 
of the photographic film. Images were analysed using the 
Scion-beta 2 program. 
Statistical analysis 
Three independent e'.(periments were run for each experimen-
tal condition. Results ru;e expressed as the mean± S.E.M. Sta-
tistical analysis of the data was performed by Student's t-test. 
Scatchard analysis [13] ofth,e raw data from binding experi-
ments was performed using the LIGAND program of NIH, 
in order to estimate receptor number and binding affinity con-
stants. 
Results 
Binding of 1251-AGE-BSA in osteoblastic cells 
We have previously reported that UMR106 and MC3T3El 
cells can specifically bind, take up and degrade AGE-BSA 
in a saturable and time-dependent manner. In addition, we 
have shown that these osteoblastic cells possess membrane-
associated 18-50 kDa receptors/binding proteins with af-
finity for 1251-AGE-BSA [13]. To investigate the possible 
regulation of these receptors by osteoblastic exposure to 
AGE-modified matrices, cells were grown either on control 
collagen or on AGE-collagen for 72 h. Radioligand binding 
studies were then performed with both cell lines, using 125I-
AGE-BSA as specific ligand. Scatchard analysis of the data 
showed different results for each cell line (Fig. 1 and Table 
1). In the case of the UMR106 osteosarcoma-derived cell 
line, exposure to extracellular AGEs halved the cellular den-
sity (Ro) of AGE-binding sites, but doubled the affinity con-
stant (K.) of these sites for AGEs. For the non-transformed 
MC3T3El preosteoblastic cells, a more cotnplex effect was 
observed: the cells grown on AGE-modified collagen, ap-
parently expressed two kinds of AGE-binding sites, which 
could be distinguished on the basis of their affinity for AGE. 
However, the total number of binding sites per cell was es-
sentially the same as for MC3T3El cells grown on control 
collagen. These results suggest that the expression of vari-
ous AGE-binding receptors could be modulated by the ex-
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Fig. I. Effect of AGE-modified collagen on 1251-AGE-BSA binding to os-
teoblastic cells. UMR106 and MC3T3El cells were grown on collagen or 
AGE-collagen for 72 h. After this incubation period, 1251-AGE-BSA bind-
ing was assayed as described in 'Materials and methods'. Scatchard plots 
for UMR106 and MC3T3EI cells represent the mean of 3 independent 
experiments performed by triplicate. 
posure of osteblast-like cells to extracellular AGE-modified 
proteins. 
Basal and AGE-modulated expression of RAGE in 
osteoblast-like cells 
In other experiments with UMR106 and MC3T3El oste-
oblastic cells, we assessed the basal expression of RAGE 
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Table l. Kinetic parameters resulting from the Scatchard analysis of binding data of 1251-AGE-BSA to osteoblast-like cells 
Cell type Collagen matrix K.' (M-1) Ro (sites/cell) 
UMR106 Control 0.82 105 2.5 107 
1.2 107 AGE-modified 1.80 105 
MC3T3El Control 0.23 106 5.1 107 
4.0 107 AGE-modified 1.7 106 0.11 106 
Data represent the mean of 3 independent experiments. KA - affinity constant; Ro - number of sites/cell. 
by immunoblot analysis. The expression of RAGE was also 
measured after culturing both cell lines for 24 h in the pres-
ence of different concentrations of BSA or AGE-BSA. Rep-
resentative Western blots with RAGE-immunoreactive bands 
are shown in Fig. 2. The antibody recognized a major band 
of approximately 50 kDa, which is consistent with the results 
of other authors [2i]. After 24 h, AGE-BSA significantly 
increased RAGE protein expression in UMR106 osteosar-
coma cells, in a dose-respoqse manner (Fig. 2A). However, 
no AGE-induced difference in RAGE expression was ob-
served in the proliferating.MC3T3El pre-osteoblasts, when 
they were submitted to the same conditions (Fig. 2B). 
To further investigate the expression of RAGE protein in 
the different developmental stages of the MC3T3El line, 
these cells were grown either on control or AGE-modified 
collagen for various periods of time. The immunoblotting of 
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MC3T3El cellular lysates (Fig. 3A), obtained after having 
cultured the cells on control or glycated matrices for 24 h 
(proliferating pre-osteoblasts), 1 week (differentiated stage), 
or 3 weeks (mineralizing stage), indicated a development-
and AGE-dependent regulation of RAGE expression in this 
cell line (Fig. 3). In the proliferating stage, cells expressed 
similar levels of RAGE when grown on control or AGE-
modified collagen. These results are in agreement with the 
experiments indicated above, performed with MC3T3El pre-
osteoblasts in the presence of BSA or AGE-BSA for 24 h (Fig. 
2). However, when MC3T3El cells were cultured on AGE-
collagen for 1 week, a significant increase was observed in 
the expression of RAGE. Finally, when cultures were ex-
tended to 3 weeks (mineralising osteoblasts), AGE-modified 
collagen induced a statistically significant decrease in the 
expression of RAGE (Fig. 3). 
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Fig. 2. Expression of RAGE in osteoblastic cells. UMR106 and MC3T3El osteoblasts were incubated with different concentrations of BSA or AGE-BSA 
for 24 h. After this incubation period, RAGE expression was analyzed by Western blot using a specific anti-RAGE antibody at a dilution of 1:1500. Blot 
were developed using a colorimetric reagent. (A) Bands corresponding to 50 kDa of RAGE protein. (B) Quantitation of RAGE protein was analyzed using 
the Scion-beta 2 program. 
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Fig. 3. Regulation of RAGE expression throughout the MC3T3E I osteob-
last developmental stages. MC3T3E I cells were grown on collagen or AGE-
modified collagen for 24 h, 1 week or 3 weeks. At the end of the culture 
period, RAGE expression was analyzed as described in 'Materials and meth-
ods'. (A) Bands corresponding to RAGE proteins were developed using a 
chemoluminescent method. Lanes corresponding to cells grown on colla-
gen are I, 3 and 5; lanes corresponding to cells grown on AGE-collagen 
are 2, 4 and 6. (B) Quantitation of RAGE protein was analyzed using the 
Scion-beta 2 program. Results are expressed as mean± S.E.M. of 5 inde-
pendent experiments. Differences between collagen and AGE-collagen are: 
*p < 0.002; **p < 0.001. 
AGEs regulate ERK activation in osteoblast-like cells 
To determine the activated status of ERK 1/2, Western blots 
with anti-phospho-ERK (P-ERK) and anti-ERK were per-
formed, and the ratio of P-ERK to total ERK was determined 
for each experimental condition. As can be seen in Fig. 4, AGE-
modified BSA induced the activation of ERK in UMR106 
osteoblasts cultured for 24 h, in a dose-dependent manner. 
A similar pattern was observed in the AGE-induced up-
regulation of RAGE expression (Fig. 2A). 
In MC3T3El cells, AGE-induced regulation of ERK acti-
vation was found to be dependent on the stage of osteoblastic 
development (Fig. 5). In the proliferative (pre-osteoblastic) 
stage, no differences were observed in the relative amount 
of P-ERK when cells were grown on control or AGE-modi-
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Fig. 4. Activation of ERK in osteoblast-like cells. UMR106 cells were 
grown for 24 h in the presence of different doses of BSA or AGE-BSA. Cells 
were lysated and extracts were submitted to Western blotting to analyze P-
ERK and ERK expression. (A) Bands corresponding to 42/44 kDa proteins 
are indicated. (B) Quantitation of bands was carried out by densitometry 
and analyzed using the Scion-beta 2 program. The activation of ERK is 
expressed as the ratio between phosphorylated and unphosphorylated forms 
of ERK. 
fled collagen for 24 h. However, after culturing the osteo-
blasts for 1 week, AGE-collagen increased the relative amount 
of P-ERK in differentiated MC3T3El cells. In the end, when 
the osteoblasts reached their mineralising stage (3-week cul-
tures), AGE-collagen significantly decreased the activation 
of ERK. These results suggest that AGE moieties can modu-
late the activation of ERK, in a manner which is dependent 
on the degree of osteoblastic maturation. In addition, this 
regulation of ERK activation by AGE-modified collagen 
follows the same pattern as the AGE-induced changes in 
RAGE expression, throughout the developmental stages of 
MC3T3El osteoblasts. 
Discussion 
The present study shows that short-, medium- or long-term 
exposure of osteoblast-like cells to extracellular AGE-modi-
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Fig. 5. Modulation of relative amounts of P-ERK throughout the develop-
mental stages of MC3T3El cells. Osteoblasts were grown on collagen or 
AGE-modified collagen for 24 h, 1 week or 3 weeks. At the end of the 
culture period, ERK activation was analyzed as described in 'Materials and 
methods'. (A) Bands corresponding to P-Erk and Erk proteins are indicated. 
Lanes l, 3 and 5 correspond to cells grown on collagen; lanes 2, 4 and 6 
correspond to cells grown on AGE-collagen. (B) Quantitation of P-Erk and 
Erk was analyzed using the Scion-beta 2 program. Results are expressed as 
mean ± S.E.M. of 3 independent experiments. Differences between colla-
gen and AGE-collagen are: *p < 0.05; **p < 0.02. 
fled proteins regulates the expression of RAGE, the affinity 
constant and cellular density of membrane-associated AGE-
specific receptors. It also modulates the activation of the sig-
nal transduction pathway involving ERK. In earlier studies, 
we had found that incubation of osteoblastic cells with AGE-
BSA or AGE-collagen induced changes in their growth, de-
velopment and mineralising potential, and in their secretion 
of IGF-I and IGFBPs [9, 10, 14]. In addition, we had also 
found that osteoblasts growing on plastic dishes (not coated 
with collagen) expressed 18-50 kDa AGE-binding proteins, 
and that maturation of these cells through their successive 
developmental stages (proliferation/differentiation/minerali-
sation) induced a 4-fold decrease in the receptors' affinity 
constant for AGEs, but did not change the total number of 
AGE-binding sites per cell [13]. Put together, these previous 
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results led us to hypothesize that several AGE receptors could 
be present in osteoblastic cells, any (or all) of which could 
be mediating the biological effects of AGEs on osteoblasts. 
In this study, we initially investigated the cellular density 
and affinity constant of AGE-binding sites in osteoblastic 
cells grown for 72 h either on control or AGE-modified colla-
gen matrices. Surprisingly, we found that the affinity constants 
of AGE-binding sites in osteoblasts grown on unmodified 
collagen, were significantly lower than the corresponding 
(same culture time) affinity constants which we had observed 
in previous studies with osteoblasts growing on plastic dishes 
[13]. Thus, we found a 5-fold decrease K. in the case of 
UMR106cells, and a 7-folddecrease in thecaseofMC3T3El 
pre-osteoblasts. However, the cellular density of AGE-bind-
ing sites was similar in osteoblasts grown on collagen (present 
study) and plastic (previous study). These results probable 
reflect a regulation of AGE-binding sites due to the interac-
tion of type-I collagen with osteoblastic receptors such as 
integrins. 
When osteoblasts were grown 72 h on AGE-modified 
collagen, cell-line specific effects were observed (Fig. l, 
Table 1). In the case ofUMR106 transformed cells, growth 
on AGE-collagen vs. control collagen halved the cellular 
density of AGE-binding sites while doubling their affinity 
constant for AGE. However, a more complex pattern was 
observed for the MC3T3El non-transformed pre-osteoblasts: 
cells grown on AGE-modified collagen showed two kinds of 
AGE-binding sites, which could be distinguished according 
to their affinity constants for AGEs. The higher affinity sites 
possessed an affinity constant 7~fold greater than that of 
MC3T3El cells grown on control collagen. Moreover, the 
lower affinity sites had an affinity constant approximately half 
of that observed in cells growing on unmodified-collagen. On 
the other hand, the total number of binding sites per cell was 
approximately the same for MC3T3El pre-osteoblasts grown 
on control or AGE-modified collagen. 
All of the observed changes in the kinetic parameters of 
AGE-binding sites of the osteoblastic cells grown on AGE-
collagen vs. control collagen, may be attributed to multiple 
causes. Thus, they could be the consequence of an increase 
in the interaction between extracellular AGEs and their spe-
cific osteoblastic receptors, or the consequence of a decrease 
in the interaction of other cellular receptors ( such as integrins) 
and their consensus sequences on type-I collagen (which may 
be blocked by AGEs moieties) as we have previously sug-
gested [14]. Additionally, the differences observed in the 
effect of AGE-collagen on UMR106 and MC3T3El cells 
might be due to different responses to AGEs of transformed 
vs. non-transformed, and/orphenotypically mature vs. imma-
ture, cell lines. Whatever the causes, ultimately all of the 
changes in the kinetic parameters of osteoblastic AGE-bind-
ing sites which we have observed in the present study (and, 
for that matter, in previous studies [13]), could merely be 
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reflecting a modification in the relative abundance of the 
different receptors which might be present (e.g. RAGE, 
galectin-3). In this sense, recent results obtained by Takagi 
et al. pointed to RAGE as a plausible mediator for AGE-in-
duced effects on osteoblastic cells [8]. These investigators 
found that primary cultures of human osteoblasts expressed 
mRNA which was specific for RAGE (although they did not 
actually demonstrate the presence of RAGE protein in these 
cultures). They also found that AGE-BSA induced the nuclear 
translocation of the transcription factor NF-KB in MC3T3El 
pre-osteoblastic cells (proliferative stage). 
The receptor RAGE has been shown to be expressed by a 
number of cell types, including neurons, microglia, endothe-
lial cells, mononuclear phagocytes and vascular smooth 
muscle cells [22]. Engagement of RAGE by AGEs can re-
sult in enhanced expression of adhesion molecules, cytokines 
and growth factors. Its binding also modulates gene expres-
sion by triggering a signal transduction cascade involving 
p21 ras, ERKl/2, CDC42-Rac and activation (nuclear translo-
cation) of NF-KB [23, 24]. Incubation of RAGE with AGEs 
induces the up-regulation,of RAGE, possibly as a conse-
quence of the interaction of NF-KB with two recognition sites 
for this transcription factor which are present in the promoter 
region of the RAGE gene [25]. 
In this study we were able to confirm that UMR106 and 
MC3T3El osteoblastic cells do in fact express RAGE. The 
next step consisted in investigating whether the exposure of 
these osteoblasts to extracellular AGEs could modulate the 
expression of RAGE. In our culture conditions, we found that 
the presence of extracellular AG Es directly modified osteob-
lastic RAGE expression, in a manner which was dependent 
on the concentration of AGE, on cell type, and on the stage 
of osteoblastic development. After a 24 h incubation with 
UMR106 osteosarcoma cells, soluble AGEs (AGE-BSA) 
induced an increase in the expression of RAGE at doses of 
200 and 500 µg protein/ml, concentrations which we have 
previously shown to stimulate UMR106 expression of alka-
line phosphatase (ALP) [9]. In the case of the MC3T3El 
calvaria-derived cells, the effect of AGEs on RAGE expres-
sion depended on the stage of osteoblastic maturation. After 
a 24 h culture with either AGE-BSA or AGE-collagen (pro-
liferating pre-osteoblasts), no effect was observed regarding 
MC3T3El expression of RAGE when compared with un-
modified BSA or collagen. To evaluate the medium- and long-
term effect of AGEs on RAGE expression, MC3T3El cells 
were grown either on control or AGE-modified collagen. 
Type I collagen was selected since this protein alone accounts 
for> 85% of bone extracellular matrix protein. In addition, 
we have recently shown that the accumulation of AGEs on 
type I collagen can regulate osteoblastic growth [14]. In the 
present study, after MC3T3El osteoblasts were cultured for 
one week ( differentiated osteoblasts) AGE-collagen induced 
an increase in the expression of RAGE, compared to control 
collagen. Interestingly, exposure of these osteoblasts to AGE-
collagen for one week enhances their expression of ALP, as 
we have previously described [14]. Finally, when MC3T3El 
cultures in this study were extended to 3 weeks (mineralis-
ing cultures), osteoblasts grown on AGE-modified collagen 
vs. control collagen showed a decrease in their expression 
of RAGE. In our previous study [14], this kind of exposure 
to AGE-collagen was associated with a decrease in the num-
ber of surviving cells, and with a decrease in the formation 
of nodules of mineralisation. 
We next addressed the issue of the possible signal trans-
duction pathways which could be activated in osteoblasts as 
a consequence of AGEs/RAGE interaction. In this sense, 
Bierhaus et al. have recently proposed that a difference must 
be made between acute (min to h) and chronic (days to weeks) 
activation of RAGE by its ligands [26]. In the case of acute 
AGEs/RAGE interactions, stimulus-induced degradation of 
IKBa. and IKBl3 allows free NF-KB p65 to translocate to the 
nucleus and activate gene transcription (however, IKBa. tran-
scription is also increased and eventually limits the availabil-
ity of free NF-KB p65, closing an autoregulatory loop). In the 
case of chronic activation of RAGE, an increase in the tran-
scription and protein synthesis of NF-KB p65 eventually over-
rides the acute autoregulatory loop, producing sustained 
NF-KB activation. ERK-1 and ERK-2 can promote NF-KB 
activity (and eventually its transcription) independently of 
IKBa. degradation, most probably by modulating NF-KB 
binding to DNA. In this way, ERK 1/2 is probably important 
in both acute and chronic phases of RAGE activation. 
Our present results show that soluble and extracellular ma-
trix AGE-modified proteins can activate osteoblastic ERKs by 
inducing their phosphorylation. We found this activation of 
ERK to parallel the AGE-induced regulation of RAGE ex-
pression. In the case of UMR 106 osteosarcoma-derived cells, 
a 24 h incubation with AGE-BSA dose-dependently induced 
an increase in the activation of ERK. When MC3T3El cells 
were studied, an AGE-associated regulation of ERK activa-
tion was observed, which was dependent on the osteoblastic 
stage of development. As mentioned above, these cells were 
cultured on either control or glycated type I collagen matri-
ces. In the case ofMC3T3El pre-osteoblasts (24 h), no differ-
ences could be observed in ERK activation between control 
and AGE-modified collagen. However, in phenotypically dif-
ferentiated MC3T3El cultures (1 week), AGE-modification 
of collagen was associated with an increase in the relative 
amount of P-ERK. When the osteoblasts finally achieved 
their mineralising stage (3 weeks), ERK activation was de-
creased in cells growing on AGE-collagen. 
In the case of the pre-osteoblastic MC3T3El cells (24 h 
culture), although in the present experiments we were unable 
to observe AGE-induced alterations in ERK activation, pre-
vious studies have demonstrated that in these same culture 
conditions AGE-collagen can transiently increase MC3T3El 
cell a,ttachment and proliferation [ 14]. These findings suggest 
that the early effects of AGE-modified proteins on pre-oste-
oblastic MC3T3El cells could be mediated by AGE-receptors 
other than RAGE (or, if RAGE is activated, it could be 
through a signal transduction pathway which does not involve 
ERK). Interestingly, by preliminary immunoblot studies we 
have found that both UMR106 and proliferating MC3T3El 
osteoblastic cells express readily detectable levels of galectin-
3 (our own unpublished observations). 
Overall, our results seem to indicate that although RAGE 
is expressed in all stages of osteoblastic development, a regu-
lation in the activation of ERK due to the presence of AG Es 
can only be observed at the later stages of this development 
(that is, when osteoblasts are phenotypically mature). In these 
later stages, and according to the results of other authors, 
AGEs/RAGE interaction would be expected to increase ERK 
activation in every.experimental condition (this is what we 
have observed, for example, with 24 h cultures of UMR106 
cells). However, most studies by other authors (and our own 
with UMR106 cells) were :performed with relatively short-
term cell cultures, and so. the results actually correspond to 
the effects of acute phase RAGE activation. In fact, the ef-
fect of the chronic activation of RAGE on the relative amount 
of P-ERK has not been clearly established by other investi-
gators. In our experiments with mature MC3T3El osteoblasts 
cultured 1-3 weeks in permanent contact with AGE-collagen, 
which are more akin to a setting of chronic AGEs/RAGE 
interaction, we observed that the level of ERK activation 
correlates with the osteoblastic expression of RAGE, but not 
directly with the actual presence of extracellular AGEs (al-
though AGEs is probably ultimately responsible for the 
regulation of RAGE expression). Whatever the precise 
mechanism responsible for the regulation of osteoblastic ERK 
activation, we have found that P-ERK is increased by AGEs 
in parallel with an AGE-induced enhancement of ALP expres-
sion (24 h UMR106 cultures, and 1 week MC3T3El cultures) 
[14]. We have also observed that AGEs provoke a decrease 
in osteoblastic ERK activation, in culture conditions which 
are associated with a decrease both in cell survival and in the 
formation of nodules of mineralisation (3 week MC3T3El 
cultures) [14]. In this context, it is interesting to note that a 
decrease in ERK activation would induce a relative inhibi-
tion of NF-KB DNA-binding capacity, and that NF-KB in-
hibition has been directly linked to apoptosis [27]. Thus, 
AGE-induced inhibition of P-ERK at this late stage of oste-
oblastic development could contribute to a decrease in cell 
survival, and so to a decrease in osteoblastic bone-forming 
capacity. 
The possible significance of these in vitro findings could 
be related to the pathological accumulation of AGEs that has 
been described in the cortical bone of diabetic and ageing rats 
[7, 28]. Our results could also help to explain the decrease in 
osteoblast recruitment and bone-forming capacity that has 
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been observed in vivo in patients with type 1 and type 2 dia-
betes mellitus [29]. These processes could be partly mediated 
by the presence of RAGE on osteoblasts, as we are describ-
ing in the present study. The accumulation of AGEs in bone 
extracellular matrix, and the generation of signal transduc-
tion pathways regulating ERK activation, would lastly affect 
bone turnover and could play a role in the pathogenesis of 
the osteopenia present in poorly controlled diabetic patients. 
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